Application of Cost-Effectiveness Analysis to Multiple Products: A Practical GuideByMohan V. Bala, PhD,Gary A. Zarkin, PhDMarch 1st 2002
Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day MakesBySusan G. Blitz, MD, MPH,Peter Cram, MD,Michael E. Chernew, PhD,Arnold S. Monto, MD,A. Mark Fendrick, MDMarch 1st 2002
Health-Related Quality of Life in Early Rheumatoid Arthritis: Impact of Disease and Treatment ResponseByMark Kosinski, MA,Sara C. Kujawski, MA,Richard Martin, MD,Lee A. Wanke, RPh,Mary C. Buatti, MS,John E. Ware, Jr, PhD,Eleanor M. PerfetMarch 1st 2002
Changes in Related Drug Class Utilization after Market Withdrawal of CisaprideByMargaret R. Glessner, PharmD,Debra A. Heller, PhDMarch 1st 2002
Development and Maintenance of a Community-Based Hepatitis C RegistryByBarbara P. Yawn, MD, MSC,Lilliana Gazzuola, MD,Peter C. Wollan PhD,W. Ray Kim, MD, MBAMarch 1st 2002
Use of Alternative Pharmacotherapy in Management of Cardiovascular DiseasesByLarisa Chagan, PharmD,Anna Ioselovich, PharmD,Liya Asherova, PharmD,Judy W.M. Cheng, PharmD, BCPSMarch 1st 2002
